Research
Hormonal
PAP+tirzepatide was associated with lower incident PH at 1 year (RR:0.27) and 3 years (RR:0.22), and lower mortality at 1 year (RR:0.14) and 3 years (RR:0.12).
Using tirzepatide in conjunction with PAP may provide superior benefits in reducing PH and mortality for obese patients with OSA.
StrongSupportsmedium confidence
PAP+tirzepatide was associated with lower incident PH at 1 year (RR:0.27; 95% CI:0.22–0.34, NNT=28) and 3 years (RR:0.22; 95% CI:0.18–0.27, NNT=15) and lower mortality at 1 year (RR:0.14; 95% CI:0.12–0.17, NNT=9) and 3 years (RR:0.12; 95% CI:0.10–0.14, NNT=6).
Why this rating
Based on the large cohort size and retrospective study design.
Source
Adjunctive GLP-1 Receptor Agonist Therapy Lowers Incident Pulmonary Hypertension and All-cause Mortality in Obese Patients with Obstructive Sleep Apnea Treated with PAP
Samuel Governor et al. · medRxiv · 2026
cohort · n=288587Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →